Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting dug users from 1986 to 2001

Journal of Epidemiology and Community Health

Volumn 58, Issue 11, 2004, Pages 944-950

  García De La Hera, Manuela ^a   Ferreros, Inmaculada ^b   Del Amo, Julia ^a   García De Olalla, Patricia ^c   Pérez Hoyos, Santiago ^b   Mugo, Roberto ^d   Del Romero, Jorge ^e   Guerrero, Rafael ^f   Hernández Aguado, Ildefonso ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b Generalitat Valenciana   (Spain)

^c AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e CENTRO SANITARIO SANDOVAL   (Spain)

^f Red Penitenciaria de Catalunya   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG USER; GENDER DISPARITY; HUMAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADDICTION; ADOLESCENT; ADULT; ARTICLE; COVARIANCE; DISEASE COURSE; DISEASE SEVERITY; DRUG ABUSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; SEROCONVERSION; SEX DIFFERENCE; SPAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; SPAIN; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS;

EASTERN HEMISPHERE; EURASIA; EUROPE; SOUTHERN EUROPE; SPAIN; WORLD;

EID: 7044245604     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2003.017475     Document Type: Article

References (46)

1. Moore R, Chaisson E. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13:1993-42.
2. Mocroft A, Vella S, Benfield TL, et al. Chaging patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
3. Palella FJ, Delaney KM, Mooman AC, et al. Declining Morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 2001;338:853-60.
4. Dray-Spira R, Lert F. Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy. AIDS 2003;17:283-90.
5. Farzadegan H, Hoover DR, Astemborski J, et al. Sex diferences in HIV-1 viral load and progression to AIDS. Lancet 1998;352:1510-14.
6. Prins M, Robersotson JR, Brettle RP, et al. Do gender differences in CD4 counts matter? AIDS 1999;13:2361-4.
7. Napravnik S, Poole Ch, Thomas JC, et al. Gender difference in HIV RNA levels: a meta-analysis of published studies. J AIDS 2002;31:11-19.
8. Gandhi M, Bacchetti P, Miotti P, et al. Does patient sex affect human immnunodeficiency Virus levels? Clin Inf Dis 2002;35:313-22.
9. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
10. Cozzi Lepri A, Pezzotti P, Dorrucci M, et al. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and follow for up to nine years from seroconversion. BMJ 1994;309:1537-42.
11. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001;344:720-5.
12. Suligoi B. The natural history of human immunodeficiency virus infection among women as compared with men. Sex Transm Dis 1997;24:77-83.
13. CASCADE Colaboration. Survival after introduction of HAART in people with known duration of HIV infection. Lancet 2000;355:1158-9.
14. Dorrucci M, Balducci M, Pezzotti P, et al. Temporal change in the rate of progression to death among Italians with know date of HVI seroconvesion: estimates of the population effect of treatment. J AIDS 1999;22:65-70.
15. Pezzotti P, Galai N, Vladov D, et al. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVA and ISS studies. J AIDS 1999;20:275-82.
16. Gange JS, Barrón Y, Greenblatt RM, for the Women's Interagency HIV Study Collaborative Study Group, et al. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health 2002;56:153-9.
17. Melnick S, Sherer R, Louis T, et al. Survival and disease progression according to gender of patients with HIV infection: the Terry Beirn community programs for clinical researche on AIDS. JAMA 1994;272:1915-21.
18. Hubert JB, Ruozioux C, Baufassa F, et al. SEROCO Study Group. Gender, disease progression and response to HAART. XIV international conference on AIDS, Barcelona, 2002:1448.
19. Moore AL, Sabin CA, Johnson MA, et al. Gender and clinical outcomes after highly active antiretroviral treatment: a cohort study. J AIDS 2002;29:197-202.
20. Pérez-Hoyos S, Del Amo J, Muga R, and GEMES, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003;17:1-7.
21. Cascade Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of infection in Europe: results from CASCADE. HIV Medicine 2000;1:224-31.
22. Prins M, Hernandez Aguado IH, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997;11:1747-56.
23. Webber MP, Schoenbaum EE, Gourevitch MN, et al. A prospective study of HIV disease progression in female and male drug users. AIDS 1999;13:257-62.
24. Hernández Aguado I, Aviñó MJ, Pérez Hoyos S, et al. Human immunodeficiency virus (HIV) infection in porenteral drug users: evolution of the epidemic over 10 years. Int J Epidemiol 1999;28:335-40.
25. Centra Nacional de Epidemiología. Vigilancia del SIDA en España. Situación al 30 de junio de 2003. Centro Nacional de Epidemiología. http://www.msc.es/sida/epidemiologia.
26. Castilla J, Martinez de Aragón MV, Gutierrez A, et al. Impact of human immunodeficiency virus infection on mortality among young men and women in Spain. Int J Epidemiol 1997;26:1346-51.
27. GEMES. AIDS incubation period in Spain before highly active antiretroviral therapy. Med Clin (Barc) 2000;115:681-6.
28. Pérez-Hoyos S, Ferreros I, Del Amo J, et al. Imputation of HIV seroconversion time in a cohort hemophiliacs. Gac Sant 2003;17:474-82.
29. Del Amo J, Del Romero J, Barrasa A, and the Grupo de Seroconvertares de la Comunidad de Madrid, et al. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex Transm Dis 2002;78:255-60.
30. Pérez-Hoyos S, Aviñó MJ, Hernández-Aguodo I, et al. AIDS-free time and survival of a injecting drug users HIV seroconversion cohort. Gac Sant 1999;13:337-45.
31. Muga R, Egea JM, Navio M, et al. Mortality in a cohort of intravenous drug users before the introduction of potent HIV therapy. Med Clin (Barc) 1999;112:721-5.
32. Barrasa A, Castilla J, Pereira J, et al. Estimating the completeness of AIDS reporting in Spain. Gac Sanit 2001;15:482-9.
33. Ajdacic-Gross V, Zellweger U, Wang J, et al. How complete is AIDS surveillance in Europe? An eagle eye comparison with mortality data. J Epidemiol Community Health 2001;55:52-6.
34. Ministerio de Sanidad y Consumo Institute Nacional de la Salud. Clasificación Internacional de Enfermedades, 9th revisión, modificación clínica (CIE-9-MC). Madrid: Ministerio de Sanidad y Consumo, 1988.
35. Pérez_Hoyos S, Ferreros I, Sanvicenç A, et al. Evolución del nivel de CD4 tras el inicio del tratamiento HAART en la cohorte de seroconvertares de GEMES. Gac Sanit 2002;16(suppl 1):33-132.
36. García de la Hera M, Ruiz I, Pérez-Hoyos S, et al. Health services utilization according to gender in a cohort of intravenous drug users infected with HIV. Med Clin (Barc) 2003;120:489-93.
37. Davies AG, Dominy NJ, Peters AD, et al. Gender differences in HIV risk behaviour of injecting drug users in Edinburgh. AIDS Care 1996;8:517-27.
38. Garcia de la Hera M, Ruiz I, Hernandez-Aguado I, et al. Gender differences in HIV risk behaviours in intravenous drug users who are not prostitutes. Women Health 2001;34:1-13.
39. Evans JL, Hahn JA, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO study). Urban Health 2003;80:137-46.
40. Muga R, Roca J, Egea JM, et al. Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. J AIDS 2000;23:332-8.
41. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267-74.
42. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002;113:91-8.
43. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497-503.
44. Mocraft A, Brettle R, Kirk O, for the EuroSida Study group, et al. Change in the cause of death among HIV positive subjects across Europe: results from the EuroSida study. AIDS 2002;16:1663-11.
45. Muñoz A, Gange SJ, Jacobson LP. Ditinguishing efficacy, individual effectivenes and population effectiveness of therapies. AIDS 2000;14:754-6.
46. Tarwater PM, Mellors J, Gore ME, et al. Methods to asses population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol 2001;154:675-81.